Arecor Therapeutics（6UI）株式概要Arecor Therapeutics plcはバイオ医薬品会社で、糖尿病およびその他の適応症の製品開発に注力している。 詳細6UI ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金0/6報酬今年は黒字化を達成 リスク分析German市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( €29M )財務結果に影響を与える大きな一時的項目 意味のある収益がありません ( £2M )すべてのリスクチェックを見る6UI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW467,951 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA467,951 investors already sharing narrativesYour Fair Value€Current Price€0.65766.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-9m5m2016201920222025202620282031Revenue UK£226.4kEarnings UK£123.1kAdvancedSet Fair ValueView all narrativesArecor Therapeutics plc 競合他社NovogeniaSymbol: MUN:7V0Market cap: €69.6m2investSymbol: XTRA:2INVMarket cap: €62.9mGenetics Generation AdvancementSymbol: TPEX:4160Market cap: NT$1.1bGeneBioTech LtdSymbol: KOSDAQ:A086060Market cap: ₩40.2b価格と性能株価の高値、安値、推移の概要Arecor Therapeutics過去の株価現在の株価UK£0.6552週高値UK£0.9452週安値UK£0.48ベータ-0.211ヶ月の変化0%3ヶ月変化0.78%1年変化31.58%3年間の変化-69.63%5年間の変化-75.00%IPOからの変化-76.95%最新ニュースお知らせ • Aug 14Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed JournalArecor Therapeutics plc announced the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic (PK) and pharmacodynamic (PD) profile regardless of body mass index (BMI) levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association's (ADA) Scientific Sessions. The published study, A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI, evaluated the PK, PD and safety of AT278 (500U/mL) compared with standard concentration (U100; 100U/mL) insulin aspart and U500 human regular insulin (500U/mL). Key study findings include: AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. Faster absorption led to a significantly greater glucose-lowering effect within the first hour following administration. AT278 maintained its ultra-rapid onset characteristics independent of BMI, distinguishing it from standard insulin apart. Overall, insulin exposure and glucose-lowering activity remained comparable while maintaining a favourable safety profile. AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.Board Change • May 21High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Non-Executive Chairman Andy Richards is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 29Arecor Therapeutics plc, Annual General Meeting, May 28, 2026Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdomお知らせ • Mar 30Arecor Therapeutics plc to Report Fiscal Year 2025 Results on Apr 13, 2026Arecor Therapeutics plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 13, 2026お知らせ • Sep 24Arecor Therapeutics plc to Report First Half, 2025 Results on Sep 25, 2025Arecor Therapeutics plc announced that they will report first half, 2025 results on Sep 25, 2025お知らせ • Jul 16Arecor Establishes New Scientific Advisory BoardArecor Therapeutics plc announced the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics. Members of the Arecor Scientific Advisory Board include: David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Senior Fellow of the UCD Conway Institute. His research focuses on oral peptide delivery and nanomedicines, with over 300 research publications and 12 patents in these areas. He is an elected Fellow of both the Controlled Release Society and the American Association of Pharmaceutical Scientists, and is an elected member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research Ireland Centre for Medical Devices (CURAM) and current coordinator of BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides. He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by Ireland's Minister of Health as Chairperson to the National Research Ethics Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the University of Cambridge, followed by a postdoctoral fellowship at Stanford University, CA, USA, before spending 10 years at Elan Biotechnology Research. Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath, where his research examines mechanisms controlling trans-epithelial migration and tight junction regulation, as well as the fate of biopharmaceuticals in subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific Officer of Applied Molecular Transport (now Cyclo Therapeutics), which directed the advancement of technology utilising endogenous pathways for efficient epithelial transcytosis. His career includes leadership roles at ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release Society, been selected to its College of Fellows, and received its Founders Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016. Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of California and a PhD in Human Anatomy and Cell Biology from the UCD School of Medicine. Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, with research focused on the absorption distribution and elimination profiles of drugs, as well as developing novel formulation approaches to optimise these profiles. He has published over 270 peer reviewed papers, his research programmes have attracted over $35m in funding, and is an inventor on more than 15 separate patent families. He is a Clarivate Analytics highly cited researcher, a fellow of the American Association of Pharmaceutical Scientists and an Editorial Board member for Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in Pharmaceutics from the University of Nottingham.最新情報をもっと見るRecent updatesお知らせ • Aug 14Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed JournalArecor Therapeutics plc announced the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic (PK) and pharmacodynamic (PD) profile regardless of body mass index (BMI) levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association's (ADA) Scientific Sessions. The published study, A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI, evaluated the PK, PD and safety of AT278 (500U/mL) compared with standard concentration (U100; 100U/mL) insulin aspart and U500 human regular insulin (500U/mL). Key study findings include: AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. Faster absorption led to a significantly greater glucose-lowering effect within the first hour following administration. AT278 maintained its ultra-rapid onset characteristics independent of BMI, distinguishing it from standard insulin apart. Overall, insulin exposure and glucose-lowering activity remained comparable while maintaining a favourable safety profile. AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.Board Change • May 21High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Non-Executive Chairman Andy Richards is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 29Arecor Therapeutics plc, Annual General Meeting, May 28, 2026Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdomお知らせ • Mar 30Arecor Therapeutics plc to Report Fiscal Year 2025 Results on Apr 13, 2026Arecor Therapeutics plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 13, 2026お知らせ • Sep 24Arecor Therapeutics plc to Report First Half, 2025 Results on Sep 25, 2025Arecor Therapeutics plc announced that they will report first half, 2025 results on Sep 25, 2025お知らせ • Jul 16Arecor Establishes New Scientific Advisory BoardArecor Therapeutics plc announced the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics. Members of the Arecor Scientific Advisory Board include: David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Senior Fellow of the UCD Conway Institute. His research focuses on oral peptide delivery and nanomedicines, with over 300 research publications and 12 patents in these areas. He is an elected Fellow of both the Controlled Release Society and the American Association of Pharmaceutical Scientists, and is an elected member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research Ireland Centre for Medical Devices (CURAM) and current coordinator of BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides. He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by Ireland's Minister of Health as Chairperson to the National Research Ethics Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the University of Cambridge, followed by a postdoctoral fellowship at Stanford University, CA, USA, before spending 10 years at Elan Biotechnology Research. Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath, where his research examines mechanisms controlling trans-epithelial migration and tight junction regulation, as well as the fate of biopharmaceuticals in subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific Officer of Applied Molecular Transport (now Cyclo Therapeutics), which directed the advancement of technology utilising endogenous pathways for efficient epithelial transcytosis. His career includes leadership roles at ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release Society, been selected to its College of Fellows, and received its Founders Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016. Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of California and a PhD in Human Anatomy and Cell Biology from the UCD School of Medicine. Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, with research focused on the absorption distribution and elimination profiles of drugs, as well as developing novel formulation approaches to optimise these profiles. He has published over 270 peer reviewed papers, his research programmes have attracted over $35m in funding, and is an inventor on more than 15 separate patent families. He is a Clarivate Analytics highly cited researcher, a fellow of the American Association of Pharmaceutical Scientists and an Editorial Board member for Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in Pharmaceutics from the University of Nottingham.お知らせ • May 07Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdomお知らせ • Apr 10Arecor Therapeutics plc to Report Fiscal Year 2024 Final Results on Apr 22, 2025Arecor Therapeutics plc announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on Apr 22, 2025お知らせ • Nov 19Arecor Therapeutics plc Appoints David Ellam as Interim Chief Financial OfficerArecor Therapeutics plc announced the appointment of David Ellam as Interim Chief Financial Officer (CFO), effective immediately. David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, Silence Therapeutics and, more recently, Sixfold Bioscience. Early in his career, he qualified as an accountant at PwC, transitioning to a variety of financial and internal audit roles at companies including Smith & Nephew.Reported Earnings • Sep 27First half 2024 earnings released: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)First half 2024 results: UK£0.15 loss per share (further deteriorated from UK£0.15 loss in 1H 2023). Revenue: UK£2.00m (up 20% from 1H 2023). Net loss: UK£4.64m (loss widened 2.5% from 1H 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 11Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting InsulinsArecor Therapeutics plc presents positive results from its Phase I clinical trial of the ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in Type 2 diabetics with a high body mass index (BMI), at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements and to be a critical enabler of next-generation miniaturised and longer wear insulin pumps. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid® (100 U/mL), a currently available gold standard, rapid acting insulin, in 41 participants with Type 2 diabetes and a median BMI of 29.7 kg/m2. The trial was conducted in a glucose clamp setting at the Medical University of Graz and Joanneum Research in Austria, an internationally recognised centre of excellence in the field of diabetes research. The PK/PD profile for AT278 was accelerated compared withNovoRapid®. AT278 demonstrated a 1.7-fold (95% CI 1.32; 2.96) higher glucose-lowering effect within the first 60 minutes which was statistically superior toNovoRapid®(p< 0.0001). The glucose-lowering effect remained higher up to 2 hours post-dosing (treatment ratio [95% CI] 1.19 [1.02; 1.39]). AT278 showed a faster onset of glucose-lowering effect, with a 5-minute earlier onset of action and 25-minute earlier tEarly50% GIRmax thanNovoRapid®. It also showed a faster onset of insulin exposure compared with NovoRapid, witha 5-minute faster insulin appearance and 24-minute faster tEarly50% Cmax.Insulin exposure with AT278 was 1.5-fold higher within the first 60 minutes(95% CI 1.28; 1.71). The superior early glucose-lowering effect of AT278 was maintained when the population was divided into BMI subgroups. Both insulins were well tolerated. Adverse events were mostly mild to moderate and not related to the study drugs. Arecor is continuing to explore funding options for AT278, including but not limited to co-development arrangements, to conduct a clinical pump study to further demonstrate the potential of AT278 to disrupt the market by enabling the next generation of truly miniaturised, longer-wear insulin pumps, a key focus for patients, physicians and the industry.お知らせ • Aug 02Arecor Therapeutics plc to Report Q2, 2024 Results on Sep 23, 2024Arecor Therapeutics plc announced that they will report Q2, 2024 results on Sep 23, 2024New Risk • Jul 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 30% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (€41.4m market cap, or US$44.9m).お知らせ • Jul 24Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million.Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,955,847 Price\Range: £0.9 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 173,768 Price\Range: £0.9 Transaction Features: Regulation S; Subsequent Direct ListingNew Risk • Jul 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.8m net loss in 2 years). Market cap is less than US$100m (€42.6m market cap, or US$46.1m).Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 08Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdomお知らせ • May 23Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting InsulinsArecor Therapeutics plc announced that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278, met all primary and secondary endpoints, and also demonstrated superiority to NovoRapid and Humulin R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI). AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid (100 U/mL), a currently available gold standard, rapid acting insulin treatment, in 39 participants with Type 2 diabetes within a BMI range of 25 and 39 kg/m2, in a euglycemic clamp setting. The PK/PD profile of 0.5 U/kg AT278 (500 U/mL) was also compared to a single SC dose of 0.5U/kg HumulinR U-500 (500 U/mL) in an open label manner. The trial met the primary endpoint of non-inferiority with respect to glucose lowering actions compared with NovoRapid.AT278 (500 U/mL) demonstrated a significantly accelerated (superior) early PK/PD profile compared to NovoRapid (100 U/mL), despite a 5-fold increase in concentration .AT278 (500 U/mL) demonstrated a significantly accelerated (superior) PK/PD profile compared to Humulin® R U-500 (500 U/mL), the only other insulin available at a concentration of 500 U/mL No safety signals were detected.Reported Earnings • May 17Full year 2023 earnings released: UK£0.28 loss per share (vs UK£0.32 loss in FY 2022)Full year 2023 results: UK£0.28 loss per share (improved from UK£0.32 loss in FY 2022). Revenue: UK£4.57m (up 90% from FY 2022). Net loss: UK£8.55m (loss narrowed 7.6% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe.New Risk • May 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£2.1m net loss in 3 years). Revenue is less than US$5m (UK£3.4m revenue, or US$4.3m). Market cap is less than US$100m (€48.7m market cap, or US$53.0m).お知らせ • Apr 30Arecor Therapeutics plc to Report Fiscal Year 2023 Results on May 07, 2024Arecor Therapeutics plc announced that they will report fiscal year 2023 results on May 07, 2024お知らせ • Apr 24Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024Arecor Therapeutics plc announced that Susan Lowther has decided to step down from her role as Company Secretary and as a Board Director, to pursue new opportunities. A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.お知らせ • Oct 05Arecor Therapeutics plc Provides Update on Progress of Second Phase I Clinical Study of Ultra-rapid, Ultra-Concentrated Insulin Candidate AT278Arecor Therapeutics plc announced that, in line with the update provided within its Interim Results on 14 September, the Group has taken the decision to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278. The increase in the number of subjects within the study, from 32 to 42, will increase the power of the study and, in turn, increase the value of the results for patients with high insulin needs. Results are expected in early 2024. The trial is a double blind, randomized, crossover study comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 42 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants.Reported Earnings • Sep 17First half 2023 earnings released: UK£0.15 loss per share (vs UK£0.16 loss in 1H 2022)First half 2023 results: UK£0.15 loss per share. Revenue: UK£1.67m (up 141% from 1H 2022). Net loss: UK£4.53m (loss widened 3.7% from 1H 2022). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.New Risk • Sep 15New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -UK£11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£11m). Currently unprofitable and not forecast to become profitable over next 2 years (UK£4.0m net loss in 2 years). Revenue is less than US$5m (UK£3.4m revenue, or US$4.2m). Market cap is less than US$100m (€66.7m market cap, or US$71.1m).お知らせ • Aug 10Arecor Therapeutics plc to Report First Half, 2023 Results on Sep 14, 2023Arecor Therapeutics plc announced that they will report first half, 2023 results on Sep 14, 2023お知らせ • May 06Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023, at 08:30 Coordinated Universal Time. Location: Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ London United KingdomReported Earnings • Apr 20Full year 2022 earnings released: UK£0.32 loss per share (vs UK£0.27 loss in FY 2021)Full year 2022 results: UK£0.32 loss per share (further deteriorated from UK£0.27 loss in FY 2021). Revenue: UK£2.40m (up 108% from FY 2021). Net loss: UK£9.26m (loss widened 50% from FY 2021). Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Germany.お知らせ • Jan 30Aarecor Therapeutics plc Announces Publication of Phase I Data for AT278 in Diabetes CareArecor Therapeutics plc announced that the American Diabetes Association journal, Diabetes Care, has published data from the Company's Phase I clinical trial of AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product candidate. The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People with Type 1 Diabetes', is now available online. In the Phase I clinical study in people with Type I diabetes, AT278 (500 U/mL) clearly demonstrated faster insulin absorption with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to gold-standard insulin NovoRapid® (100 U/mL) despite a 5-fold increase in concentration. AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market, and therefore, AT278 has the potential to be the first such product available to patients. It has the potential to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices. AT278 is also currently being investigated in a second Phase I trial in patients with Type 2 diabetes, to further explore the product's potential to disrupt the market as the first concentrated, yet rapid acting, insulin. The study initiated earlier this month and is expected to complete within fourth quarter of 2023.お知らせ • Nov 22Arecor Therapeutics plc Commences Second Clinical Trial with At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Type 2 DiabetesArecor Therapeutics plc announced the BASG (Bundesamt für Sicherheit im Gesundheitswesen)clearance of the Group's Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population. The approval of the CTA means that Arecor may now initiate the second Phase I clinical trial for AT278, to further explore the potential for AT278 to disrupt the market for insulin treatment, as the first concentrated, yet rapid acting insulin. AT278 has previously demonstrated a faster insulin absorption with an accelerated Pharmacokinetic (PK) and Pharmacodynamic (PD) profile compared to the lower concentration NovoRapid® (100 U/mL) in aPhase I clinical study in Type 1 diabetic patients. This type 2 diabetes trial will also focus on exploring the PK/PD profile of AT278 compared with NovoRapid® (100 U/mL), as well as Humulin-R U500®. The trial is a double blind, randomised, crossover study comparing the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 32 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants. The trial will be conducted at the Medical University of Graz, Austria, an expert clinical research facility in metabolic diseases research and euglycaemic clamp methodology, with Professor Thomas Pieber as the trial's Principal Investigator. This trial is expected to initiate within 2022 and complete within Fourth Quarter 2023.Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 11Arecor Therapeutics plc Announces Headline Results from Phase I Trial of AT247Arecor Therapeutics plc announced headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas. AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection. The superiorpharmacokinetics /pharmacodynamics (PK/PD)profile of a single dose of AT247 compared with gold standard insulins NovoLog® and Fiasp® has been previously demonstrated in a Phase I study. This second clinical study further confirms that AT247 has a superior PK profile compared with NovoLog® and Fiasp®, showing a statistically significant difference meeting the trial's co-primary endpoint. AT247 also demonstrated a statistically superior early glucose lowering effect in the trial's second primary endpoint compared with NovoLog® which was calculated from baseline corrected Incremental AUC GIR (Glucose Infusion rate) 0-60min (mg/kg) during post-hoc analysis. In addition, AT247 demonstrated a similar glucose lowering profile to Fiasp®, however it did not meet superiority for this endpoint within this study. The trial further demonstrated that AT247 can be safely and effectively delivered via continuous SC infusion using an insulin pump. With a superior PK profile and promising PD results, this study supports the potential that AT247 can enable even more effective disease management for people with Type I diabetes using fully automated delivery of insulin via a pump in closed loop mode. the double-blind, randomised, three-way cross over Phase I clinical study in 24 male and female participants with Type I diabetes, the pharmacokinetics (PK) and pharmacodynamics (PD) and safety of AT247 were compared with those of NovoLog® and Fiasp®, currently available rapid acting insulin treatments, when delivered over 3 days by insulin pump. In this cross over study the PK/PD profiles following a s.c. bolus dose of 0.15 U/Kg AT247, NovoLog® and Fiasp®, delivered by insulin pump, were compared in a euglycemic clamp setting. The basal rate of insulin dosing was set at 0.02 U/Kg/Hr during the clamp period. No safety signals were detected. Detailed data from the trial will be submitted for presentation at a future international diabetes conference.お知らせ • Sep 21Arecor Therapeutics plc Presents Positive Data for At278 at EasdArecor Therapeutics plc presented positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the European Association for the Study of Diabetes (EASD) Annual Meeting. The abstract, "Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500",is being presented as part of the Short Oral Discussion Session A, "How complicated is type 1 diabetes?" (11:45-12:45 CEST). AT278 is Arecor's ultra-concentrated (500 U/mL), ultra-rapid acting insulin candidate, formulated using the Company's ArestatTM technology and designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements. In the double-blind, randomised, single dose, two-period cross over Phase I clinical study (EudraCT:2020-002033-15) the pharmacokinetic (PK) and pharmacodynamic (PD) profile of AT278 was compared to NovoRapid®, the current gold standard treatment, in 38 patients with type 1 diabetes. The trial was conducted in a glucose clamp setting at the Medical University of Graz and Joanneum Research in Austria, an internationally recognised centre of excellence in the field of diabetes research. The PK/PD profile for AT278 was accelerated compared with NovoRapid®. Following dosing, AT278 showed a faster onset of insulin exposure compared with NovoRapid®, as demonstrated by an earlier onset of appearance (-6.0 min, P<0.0001), earliertEarly50%Cmax(-23.0 min, P<0.0001)and 4.0 times higher AUCInsulin,0-30min (95% CI: 3.29; 4.90). AT278 also showed a more rapid onset of glucose-lowering effect compared with NovoRapid®as demonstrated by an earlier onset of action (-9.5 min, P<0.0001) and earlier tEarly50%GIRmax (-20.0 min, P<0.0001). Overall insulin exposure and glucose-lowering effect were comparable between both insulins (AUCInsulin,0-8h treatment ratio 0.98 [95% CI: 0.92; 1.00]; AUCGIR,0-8h treatment ratio 1.02 [95% CI: 0.95; 1.09]). All reported adverse events were mild in intensity and no safety signals were detected. A further clinical trial of AT278, in people living with type 2 diabetes, is expected to be initiated later this year. The randomised, double-blind Phase I study in obese type 2 diabetes patients will recruit approximately 28 adult patients with each receiving one subcutaneous dose (0.5 U/kg) of AT278, NovoRapid® and Humulin® R U 500 in three separate treatment periods. The PK/PD profile will be measured in each treatment period in a glycemic clamp setting.Board Change • Aug 05Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元6UIDE BiotechsDE 市場7D8.3%-4.6%-0.3%1Y31.6%-1.8%3.0%株主還元を見る業界別リターン: 6UI過去 1 年間で-1.8 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: 6UI過去 1 年間で3 % の収益を上げたGerman市場を上回りました。価格変動Is 6UI's price volatile compared to industry and market?6UI volatility6UI Average Weekly Movement10.7%Biotechs Industry Average Movement6.3%Market Average Movement5.2%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.6%安定した株価: 6UIの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 6UIの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200733Sarah Howellarecor.comArecor Therapeutics plcはバイオ医薬品会社で、糖尿病およびその他の適応症の製品開発に注力している。同社は、独自のリフォーミュレーション技術プラットフォームであるArestatを通じて、糖尿病およびその他の適応症における独自の製品ポートフォリオを開発するとともに、製薬会社やバイオテクノロジー企業と協力して治療薬の改良型リフォーミュレーションを提供している。また、糖尿病患者の重症低血糖の治療に使用されるオグルオや、専門病院向け製品も提供している。さらに、I型およびII型糖尿病患者を対象にフェーズ1段階にある超速効型インスリン製剤AT247と、注射後のインスリン吸収を促進するように設計された超濃縮速効型インスリン製剤AT278を開発している。TRxバイオサイエンシズ社とは経口グルカゴン様ペプチド-1（GLP-1）受容体作動薬の製剤開発に関する共同研究を行っており、メドトロニック社とは体内埋め込み型ポンプ投与用の新規耐熱性インスリン製剤の開発に関する共同研究を行っている。アレコア・セラピューティクス社は2007年に設立され、英国のリトル・チェスターフォードに本社を置いている。もっと見るArecor Therapeutics plc 基礎のまとめArecor Therapeutics の収益と売上を時価総額と比較するとどうか。6UI 基礎統計学時価総額€29.12m収益（TTM）€1.09m売上高(TTM)€2.00m26.7xPER（株価収益率14.5xP/Sレシオ6UI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6UI 損益計算書（TTM）収益UK£1.71m売上原価UK£448.00k売上総利益UK£1.27mその他の費用UK£334.00k収益UK£932.00k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.025グロス・マージン73.86%純利益率54.38%有利子負債／自己資本比率0%6UI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 05:24終値2026/08/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Arecor Therapeutics plc 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Julie SimmondsPanmure Liberum
お知らせ • Aug 14Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed JournalArecor Therapeutics plc announced the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic (PK) and pharmacodynamic (PD) profile regardless of body mass index (BMI) levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association's (ADA) Scientific Sessions. The published study, A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI, evaluated the PK, PD and safety of AT278 (500U/mL) compared with standard concentration (U100; 100U/mL) insulin aspart and U500 human regular insulin (500U/mL). Key study findings include: AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. Faster absorption led to a significantly greater glucose-lowering effect within the first hour following administration. AT278 maintained its ultra-rapid onset characteristics independent of BMI, distinguishing it from standard insulin apart. Overall, insulin exposure and glucose-lowering activity remained comparable while maintaining a favourable safety profile. AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.
Board Change • May 21High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Non-Executive Chairman Andy Richards is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 29Arecor Therapeutics plc, Annual General Meeting, May 28, 2026Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom
お知らせ • Mar 30Arecor Therapeutics plc to Report Fiscal Year 2025 Results on Apr 13, 2026Arecor Therapeutics plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 13, 2026
お知らせ • Sep 24Arecor Therapeutics plc to Report First Half, 2025 Results on Sep 25, 2025Arecor Therapeutics plc announced that they will report first half, 2025 results on Sep 25, 2025
お知らせ • Jul 16Arecor Establishes New Scientific Advisory BoardArecor Therapeutics plc announced the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics. Members of the Arecor Scientific Advisory Board include: David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Senior Fellow of the UCD Conway Institute. His research focuses on oral peptide delivery and nanomedicines, with over 300 research publications and 12 patents in these areas. He is an elected Fellow of both the Controlled Release Society and the American Association of Pharmaceutical Scientists, and is an elected member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research Ireland Centre for Medical Devices (CURAM) and current coordinator of BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides. He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by Ireland's Minister of Health as Chairperson to the National Research Ethics Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the University of Cambridge, followed by a postdoctoral fellowship at Stanford University, CA, USA, before spending 10 years at Elan Biotechnology Research. Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath, where his research examines mechanisms controlling trans-epithelial migration and tight junction regulation, as well as the fate of biopharmaceuticals in subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific Officer of Applied Molecular Transport (now Cyclo Therapeutics), which directed the advancement of technology utilising endogenous pathways for efficient epithelial transcytosis. His career includes leadership roles at ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release Society, been selected to its College of Fellows, and received its Founders Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016. Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of California and a PhD in Human Anatomy and Cell Biology from the UCD School of Medicine. Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, with research focused on the absorption distribution and elimination profiles of drugs, as well as developing novel formulation approaches to optimise these profiles. He has published over 270 peer reviewed papers, his research programmes have attracted over $35m in funding, and is an inventor on more than 15 separate patent families. He is a Clarivate Analytics highly cited researcher, a fellow of the American Association of Pharmaceutical Scientists and an Editorial Board member for Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in Pharmaceutics from the University of Nottingham.
お知らせ • Aug 14Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed JournalArecor Therapeutics plc announced the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic (PK) and pharmacodynamic (PD) profile regardless of body mass index (BMI) levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association's (ADA) Scientific Sessions. The published study, A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI, evaluated the PK, PD and safety of AT278 (500U/mL) compared with standard concentration (U100; 100U/mL) insulin aspart and U500 human regular insulin (500U/mL). Key study findings include: AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. Faster absorption led to a significantly greater glucose-lowering effect within the first hour following administration. AT278 maintained its ultra-rapid onset characteristics independent of BMI, distinguishing it from standard insulin apart. Overall, insulin exposure and glucose-lowering activity remained comparable while maintaining a favourable safety profile. AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.
Board Change • May 21High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Non-Executive Chairman Andy Richards is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 29Arecor Therapeutics plc, Annual General Meeting, May 28, 2026Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom
お知らせ • Mar 30Arecor Therapeutics plc to Report Fiscal Year 2025 Results on Apr 13, 2026Arecor Therapeutics plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 13, 2026
お知らせ • Sep 24Arecor Therapeutics plc to Report First Half, 2025 Results on Sep 25, 2025Arecor Therapeutics plc announced that they will report first half, 2025 results on Sep 25, 2025
お知らせ • Jul 16Arecor Establishes New Scientific Advisory BoardArecor Therapeutics plc announced the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics. Members of the Arecor Scientific Advisory Board include: David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Senior Fellow of the UCD Conway Institute. His research focuses on oral peptide delivery and nanomedicines, with over 300 research publications and 12 patents in these areas. He is an elected Fellow of both the Controlled Release Society and the American Association of Pharmaceutical Scientists, and is an elected member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research Ireland Centre for Medical Devices (CURAM) and current coordinator of BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides. He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by Ireland's Minister of Health as Chairperson to the National Research Ethics Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the University of Cambridge, followed by a postdoctoral fellowship at Stanford University, CA, USA, before spending 10 years at Elan Biotechnology Research. Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath, where his research examines mechanisms controlling trans-epithelial migration and tight junction regulation, as well as the fate of biopharmaceuticals in subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific Officer of Applied Molecular Transport (now Cyclo Therapeutics), which directed the advancement of technology utilising endogenous pathways for efficient epithelial transcytosis. His career includes leadership roles at ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release Society, been selected to its College of Fellows, and received its Founders Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016. Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of California and a PhD in Human Anatomy and Cell Biology from the UCD School of Medicine. Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, with research focused on the absorption distribution and elimination profiles of drugs, as well as developing novel formulation approaches to optimise these profiles. He has published over 270 peer reviewed papers, his research programmes have attracted over $35m in funding, and is an inventor on more than 15 separate patent families. He is a Clarivate Analytics highly cited researcher, a fellow of the American Association of Pharmaceutical Scientists and an Editorial Board member for Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in Pharmaceutics from the University of Nottingham.
お知らせ • May 07Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom
お知らせ • Apr 10Arecor Therapeutics plc to Report Fiscal Year 2024 Final Results on Apr 22, 2025Arecor Therapeutics plc announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on Apr 22, 2025
お知らせ • Nov 19Arecor Therapeutics plc Appoints David Ellam as Interim Chief Financial OfficerArecor Therapeutics plc announced the appointment of David Ellam as Interim Chief Financial Officer (CFO), effective immediately. David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, Silence Therapeutics and, more recently, Sixfold Bioscience. Early in his career, he qualified as an accountant at PwC, transitioning to a variety of financial and internal audit roles at companies including Smith & Nephew.
Reported Earnings • Sep 27First half 2024 earnings released: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)First half 2024 results: UK£0.15 loss per share (further deteriorated from UK£0.15 loss in 1H 2023). Revenue: UK£2.00m (up 20% from 1H 2023). Net loss: UK£4.64m (loss widened 2.5% from 1H 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 11Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting InsulinsArecor Therapeutics plc presents positive results from its Phase I clinical trial of the ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in Type 2 diabetics with a high body mass index (BMI), at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements and to be a critical enabler of next-generation miniaturised and longer wear insulin pumps. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid® (100 U/mL), a currently available gold standard, rapid acting insulin, in 41 participants with Type 2 diabetes and a median BMI of 29.7 kg/m2. The trial was conducted in a glucose clamp setting at the Medical University of Graz and Joanneum Research in Austria, an internationally recognised centre of excellence in the field of diabetes research. The PK/PD profile for AT278 was accelerated compared withNovoRapid®. AT278 demonstrated a 1.7-fold (95% CI 1.32; 2.96) higher glucose-lowering effect within the first 60 minutes which was statistically superior toNovoRapid®(p< 0.0001). The glucose-lowering effect remained higher up to 2 hours post-dosing (treatment ratio [95% CI] 1.19 [1.02; 1.39]). AT278 showed a faster onset of glucose-lowering effect, with a 5-minute earlier onset of action and 25-minute earlier tEarly50% GIRmax thanNovoRapid®. It also showed a faster onset of insulin exposure compared with NovoRapid, witha 5-minute faster insulin appearance and 24-minute faster tEarly50% Cmax.Insulin exposure with AT278 was 1.5-fold higher within the first 60 minutes(95% CI 1.28; 1.71). The superior early glucose-lowering effect of AT278 was maintained when the population was divided into BMI subgroups. Both insulins were well tolerated. Adverse events were mostly mild to moderate and not related to the study drugs. Arecor is continuing to explore funding options for AT278, including but not limited to co-development arrangements, to conduct a clinical pump study to further demonstrate the potential of AT278 to disrupt the market by enabling the next generation of truly miniaturised, longer-wear insulin pumps, a key focus for patients, physicians and the industry.
お知らせ • Aug 02Arecor Therapeutics plc to Report Q2, 2024 Results on Sep 23, 2024Arecor Therapeutics plc announced that they will report Q2, 2024 results on Sep 23, 2024
New Risk • Jul 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 30% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (€41.4m market cap, or US$44.9m).
お知らせ • Jul 24Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million.Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,955,847 Price\Range: £0.9 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 173,768 Price\Range: £0.9 Transaction Features: Regulation S; Subsequent Direct Listing
New Risk • Jul 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.8m net loss in 2 years). Market cap is less than US$100m (€42.6m market cap, or US$46.1m).
Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 08Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom
お知らせ • May 23Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting InsulinsArecor Therapeutics plc announced that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278, met all primary and secondary endpoints, and also demonstrated superiority to NovoRapid and Humulin R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI). AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid (100 U/mL), a currently available gold standard, rapid acting insulin treatment, in 39 participants with Type 2 diabetes within a BMI range of 25 and 39 kg/m2, in a euglycemic clamp setting. The PK/PD profile of 0.5 U/kg AT278 (500 U/mL) was also compared to a single SC dose of 0.5U/kg HumulinR U-500 (500 U/mL) in an open label manner. The trial met the primary endpoint of non-inferiority with respect to glucose lowering actions compared with NovoRapid.AT278 (500 U/mL) demonstrated a significantly accelerated (superior) early PK/PD profile compared to NovoRapid (100 U/mL), despite a 5-fold increase in concentration .AT278 (500 U/mL) demonstrated a significantly accelerated (superior) PK/PD profile compared to Humulin® R U-500 (500 U/mL), the only other insulin available at a concentration of 500 U/mL No safety signals were detected.
Reported Earnings • May 17Full year 2023 earnings released: UK£0.28 loss per share (vs UK£0.32 loss in FY 2022)Full year 2023 results: UK£0.28 loss per share (improved from UK£0.32 loss in FY 2022). Revenue: UK£4.57m (up 90% from FY 2022). Net loss: UK£8.55m (loss narrowed 7.6% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
New Risk • May 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£2.1m net loss in 3 years). Revenue is less than US$5m (UK£3.4m revenue, or US$4.3m). Market cap is less than US$100m (€48.7m market cap, or US$53.0m).
お知らせ • Apr 30Arecor Therapeutics plc to Report Fiscal Year 2023 Results on May 07, 2024Arecor Therapeutics plc announced that they will report fiscal year 2023 results on May 07, 2024
お知らせ • Apr 24Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024Arecor Therapeutics plc announced that Susan Lowther has decided to step down from her role as Company Secretary and as a Board Director, to pursue new opportunities. A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.
お知らせ • Oct 05Arecor Therapeutics plc Provides Update on Progress of Second Phase I Clinical Study of Ultra-rapid, Ultra-Concentrated Insulin Candidate AT278Arecor Therapeutics plc announced that, in line with the update provided within its Interim Results on 14 September, the Group has taken the decision to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278. The increase in the number of subjects within the study, from 32 to 42, will increase the power of the study and, in turn, increase the value of the results for patients with high insulin needs. Results are expected in early 2024. The trial is a double blind, randomized, crossover study comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 42 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants.
Reported Earnings • Sep 17First half 2023 earnings released: UK£0.15 loss per share (vs UK£0.16 loss in 1H 2022)First half 2023 results: UK£0.15 loss per share. Revenue: UK£1.67m (up 141% from 1H 2022). Net loss: UK£4.53m (loss widened 3.7% from 1H 2022). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
New Risk • Sep 15New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -UK£11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£11m). Currently unprofitable and not forecast to become profitable over next 2 years (UK£4.0m net loss in 2 years). Revenue is less than US$5m (UK£3.4m revenue, or US$4.2m). Market cap is less than US$100m (€66.7m market cap, or US$71.1m).
お知らせ • Aug 10Arecor Therapeutics plc to Report First Half, 2023 Results on Sep 14, 2023Arecor Therapeutics plc announced that they will report first half, 2023 results on Sep 14, 2023
お知らせ • May 06Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023, at 08:30 Coordinated Universal Time. Location: Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ London United Kingdom
Reported Earnings • Apr 20Full year 2022 earnings released: UK£0.32 loss per share (vs UK£0.27 loss in FY 2021)Full year 2022 results: UK£0.32 loss per share (further deteriorated from UK£0.27 loss in FY 2021). Revenue: UK£2.40m (up 108% from FY 2021). Net loss: UK£9.26m (loss widened 50% from FY 2021). Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
お知らせ • Jan 30Aarecor Therapeutics plc Announces Publication of Phase I Data for AT278 in Diabetes CareArecor Therapeutics plc announced that the American Diabetes Association journal, Diabetes Care, has published data from the Company's Phase I clinical trial of AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product candidate. The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People with Type 1 Diabetes', is now available online. In the Phase I clinical study in people with Type I diabetes, AT278 (500 U/mL) clearly demonstrated faster insulin absorption with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to gold-standard insulin NovoRapid® (100 U/mL) despite a 5-fold increase in concentration. AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market, and therefore, AT278 has the potential to be the first such product available to patients. It has the potential to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices. AT278 is also currently being investigated in a second Phase I trial in patients with Type 2 diabetes, to further explore the product's potential to disrupt the market as the first concentrated, yet rapid acting, insulin. The study initiated earlier this month and is expected to complete within fourth quarter of 2023.
お知らせ • Nov 22Arecor Therapeutics plc Commences Second Clinical Trial with At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Type 2 DiabetesArecor Therapeutics plc announced the BASG (Bundesamt für Sicherheit im Gesundheitswesen)clearance of the Group's Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population. The approval of the CTA means that Arecor may now initiate the second Phase I clinical trial for AT278, to further explore the potential for AT278 to disrupt the market for insulin treatment, as the first concentrated, yet rapid acting insulin. AT278 has previously demonstrated a faster insulin absorption with an accelerated Pharmacokinetic (PK) and Pharmacodynamic (PD) profile compared to the lower concentration NovoRapid® (100 U/mL) in aPhase I clinical study in Type 1 diabetic patients. This type 2 diabetes trial will also focus on exploring the PK/PD profile of AT278 compared with NovoRapid® (100 U/mL), as well as Humulin-R U500®. The trial is a double blind, randomised, crossover study comparing the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 32 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants. The trial will be conducted at the Medical University of Graz, Austria, an expert clinical research facility in metabolic diseases research and euglycaemic clamp methodology, with Professor Thomas Pieber as the trial's Principal Investigator. This trial is expected to initiate within 2022 and complete within Fourth Quarter 2023.
Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 11Arecor Therapeutics plc Announces Headline Results from Phase I Trial of AT247Arecor Therapeutics plc announced headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas. AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection. The superiorpharmacokinetics /pharmacodynamics (PK/PD)profile of a single dose of AT247 compared with gold standard insulins NovoLog® and Fiasp® has been previously demonstrated in a Phase I study. This second clinical study further confirms that AT247 has a superior PK profile compared with NovoLog® and Fiasp®, showing a statistically significant difference meeting the trial's co-primary endpoint. AT247 also demonstrated a statistically superior early glucose lowering effect in the trial's second primary endpoint compared with NovoLog® which was calculated from baseline corrected Incremental AUC GIR (Glucose Infusion rate) 0-60min (mg/kg) during post-hoc analysis. In addition, AT247 demonstrated a similar glucose lowering profile to Fiasp®, however it did not meet superiority for this endpoint within this study. The trial further demonstrated that AT247 can be safely and effectively delivered via continuous SC infusion using an insulin pump. With a superior PK profile and promising PD results, this study supports the potential that AT247 can enable even more effective disease management for people with Type I diabetes using fully automated delivery of insulin via a pump in closed loop mode. the double-blind, randomised, three-way cross over Phase I clinical study in 24 male and female participants with Type I diabetes, the pharmacokinetics (PK) and pharmacodynamics (PD) and safety of AT247 were compared with those of NovoLog® and Fiasp®, currently available rapid acting insulin treatments, when delivered over 3 days by insulin pump. In this cross over study the PK/PD profiles following a s.c. bolus dose of 0.15 U/Kg AT247, NovoLog® and Fiasp®, delivered by insulin pump, were compared in a euglycemic clamp setting. The basal rate of insulin dosing was set at 0.02 U/Kg/Hr during the clamp period. No safety signals were detected. Detailed data from the trial will be submitted for presentation at a future international diabetes conference.
お知らせ • Sep 21Arecor Therapeutics plc Presents Positive Data for At278 at EasdArecor Therapeutics plc presented positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the European Association for the Study of Diabetes (EASD) Annual Meeting. The abstract, "Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500",is being presented as part of the Short Oral Discussion Session A, "How complicated is type 1 diabetes?" (11:45-12:45 CEST). AT278 is Arecor's ultra-concentrated (500 U/mL), ultra-rapid acting insulin candidate, formulated using the Company's ArestatTM technology and designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements. In the double-blind, randomised, single dose, two-period cross over Phase I clinical study (EudraCT:2020-002033-15) the pharmacokinetic (PK) and pharmacodynamic (PD) profile of AT278 was compared to NovoRapid®, the current gold standard treatment, in 38 patients with type 1 diabetes. The trial was conducted in a glucose clamp setting at the Medical University of Graz and Joanneum Research in Austria, an internationally recognised centre of excellence in the field of diabetes research. The PK/PD profile for AT278 was accelerated compared with NovoRapid®. Following dosing, AT278 showed a faster onset of insulin exposure compared with NovoRapid®, as demonstrated by an earlier onset of appearance (-6.0 min, P<0.0001), earliertEarly50%Cmax(-23.0 min, P<0.0001)and 4.0 times higher AUCInsulin,0-30min (95% CI: 3.29; 4.90). AT278 also showed a more rapid onset of glucose-lowering effect compared with NovoRapid®as demonstrated by an earlier onset of action (-9.5 min, P<0.0001) and earlier tEarly50%GIRmax (-20.0 min, P<0.0001). Overall insulin exposure and glucose-lowering effect were comparable between both insulins (AUCInsulin,0-8h treatment ratio 0.98 [95% CI: 0.92; 1.00]; AUCGIR,0-8h treatment ratio 1.02 [95% CI: 0.95; 1.09]). All reported adverse events were mild in intensity and no safety signals were detected. A further clinical trial of AT278, in people living with type 2 diabetes, is expected to be initiated later this year. The randomised, double-blind Phase I study in obese type 2 diabetes patients will recruit approximately 28 adult patients with each receiving one subcutaneous dose (0.5 U/kg) of AT278, NovoRapid® and Humulin® R U 500 in three separate treatment periods. The PK/PD profile will be measured in each treatment period in a glycemic clamp setting.
Board Change • Aug 05Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
